You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrametinib
Accession NumberDB08911
TypeSmall Molecule
GroupsApproved
DescriptionTrametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013.
Structure
Thumb
Synonyms
GSK 1120212
JTP 74057
Trametinib Dimethyl Sulfoxide
Trametinibum
External Identifiers
  • GSK1120212
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MekinistTablet, film coated0.5 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated.5 mg/1OralGlaxosmithkline Inc2013-06-172016-12-31Us
MekinistTablet1 mgOralNovartisNot applicableNot applicableCanada
MekinistTablet, film coated1 mg/1OralGlaxosmithkline Inc2013-06-172015-12-29Us
MekinistTablet, film coated2 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated0.5 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated0.5 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated.5 mg/1OralNovartis2016-03-17Not applicableUs
MekinistTablet0.5 mgOralNovartis2013-08-28Not applicableCanada
MekinistTablet, film coated2 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated0.5 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated2 mg/1OralNovartis2016-03-17Not applicableUs
MekinistTablet2 mgOralNovartis2013-08-28Not applicableCanada
MekinistTablet, film coated2 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated2 mgOralNovartis Europharm Limited  2014-06-30Not applicableEu
MekinistTablet, film coated2 mg/1OralGlaxosmithkline Inc2013-06-172016-12-31Us
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Trametinib dimethyl sulfoxide
1187431-43-1
Thumb
  • InChI Key: OQUFJVRYDFIQBW-UHFFFAOYSA-N
  • Monoisotopic Mass: 693.09181
  • Average Mass: 693.53
DBSALT001947
Categories
UNII33E86K87QN
CAS number871700-17-3
WeightAverage: 615.3948
Monoisotopic: 615.077875874
Chemical FormulaC26H23FIN5O4
InChI KeyLIRYPHYGHXZJBZ-UHFFFAOYSA-N
InChI
InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
IUPAC Name
N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-1H,2H,3H,4H,6H,7H-pyrido[4,3-d]pyrimidin-1-yl}phenyl)acetamide
SMILES
CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=CC=C(I)C=C1F)C1=CC(NC(C)=O)=CC=C1
Pharmacology
IndicationTrametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Structured Indications
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingNot AvailableCholangiocarcinomas / Soft-Tissue Sarcoma / Thyroid Cancers / Tumors, Solid1
1CompletedNot AvailableCancers1
1CompletedBasic ScienceCancers1
1CompletedTreatmentAdvanced and Selected Solid Tumors1
1CompletedTreatmentCancers5
1CompletedTreatmentCancers / Solid Tumours1
1CompletedTreatmentSolid Tumours3
1CompletedTreatmentTumors, Solid1
1Not Yet RecruitingTreatmentMelanoma1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Advanced Malignancy / Cancers / Oncology / Oncology Patients1
1RecruitingTreatmentCancers3
1RecruitingTreatmentCancers / Neuroblastomas1
1RecruitingTreatmentHepatic Complications / Metastatic Malignant Neoplasm in the Liver / Solid Neoplasms1
1RecruitingTreatmentHepatocellular Cancer / Liver Cancer1
1RecruitingTreatmentMelanoma1
1RecruitingTreatmentMetastatic Malignant Neoplasm in the Brain1
1RecruitingTreatmentMetastatic Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
1RecruitingTreatmentRecurrent Melanoma / Solid Neoplasms / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
1RecruitingTreatmentRecurrent Rectal Cancer / Stage IIA Rectal Cancer / Stage IIB Rectal Cancer / Stage IIC Rectal Cancer / Stage IIIA Rectal Cancer / Stage IIIB Rectal Cancer / Stage IIIC Rectal Cancer1
1RecruitingTreatmentRelapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer1
1RecruitingTreatmentTumors, Solid1
1SuspendedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1TerminatedTreatmentCancers2
1WithdrawnTreatmentLung Cancer, Non-Small Cell1
1WithdrawnTreatmentMelanoma1
1WithdrawnTreatmentMetastatic Melanoma1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2Not Yet RecruitingTreatmentColorectal Cancers / Pancreatic Cancers / Tumors, Solid1
1, 2RecruitingTreatmentAdvanced Malignancy / Advanced Solid Tumors / Cancers / Melanoma / Oncology / Oncology Patients / Tumors1
1, 2RecruitingTreatmentColorectal Cancers1
1, 2RecruitingTreatmentMelanoma1
1, 2RecruitingTreatmentMelanoma / Tumors, Solid1
1, 2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2SuspendedTreatmentAdult Solid Neoplasm / Recurrent Colon Carcinoma / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Stage IIIC Colon Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
1, 2SuspendedTreatmentExtensive Stage Small Cell Lung Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Small Cell Lung Carcinoma / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IIIA Colorectal Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Colorectal Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIC Colorectal Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1, 2SuspendedTreatmentMetastatic Melanoma / Recurrent Melanoma / Solid Neoplasms / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
2Active Not RecruitingTreatmentAdult Cholangiocarcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Hilar Cholangiocarcinoma / Localized Non-Resectable Adult Liver Carcinoma / Recurrent Adult Liver Carcinoma / Recurrent Childhood Liver Cancer / Recurrent Extrahepatic Bile Duct Carcinoma / Recurrent Gallbladder Carcinoma / Stage II Gallbladder Cancer / Stage III Childhood Hepatocellular Carcinoma / Stage IIIA Gallbladder Cancer / Stage IIIB Gallbladder Cancer / Stage IV Childhood Hepatocellular Carcinoma / Stage IV Distal Bile Duct Cancer / Stage IVA Gallbladder Cancer / Stage IVB Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Carcinoma1
2Active Not RecruitingTreatmentCancers2
2Active Not RecruitingTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentSolid Tumours1
2CompletedTreatmentCancers3
2CompletedTreatmentLung Cancer, Non-Small Cell1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMouth Neoplasms / Neoplasms, Oral1
2Not Yet RecruitingTreatmentAdenocarcinomas / Pancreatic Cancers1
2Not Yet RecruitingTreatmentBRAF Wildtype / Colorectal Cancers / KRAS Wildtype / NRAS Wildtype1
2Not Yet RecruitingTreatmentGastrointestinal Stromal Tumors1
2Not Yet RecruitingTreatmentMetastatic Melanoma1
2Not Yet RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
2RecruitingNot AvailableRecurrent Melanoma / Stage IIB Melanoma (Locally Advanced) / Stage IIC Melanoma (Locally Advanced) / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIC Melanoma / Stage IV Melanoma (Limited, Resectable)1
2RecruitingDiagnosticMelanoma1
2RecruitingTreatmentAdvanced Malignant Neoplasm / Lymphoma NOS / Refractory Malignant Neoplasm / Solid Neoplasms1
2RecruitingTreatmentBRAF V600E Mutation1
2RecruitingTreatmentBRAF V600E Mutation Present / BRAF V600K Mutation Present / Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
2RecruitingTreatmentCancers4
2RecruitingTreatmentFollicular Thyroid Cancer / Insular Thyroid Cancer / Papillary Thyroid Cancer / Recurrent Thyroid Cancer1
2RecruitingTreatmentMalignant Melanoma2
2RecruitingTreatmentMalignant Melanoma Stage IV / Melanoma / Metastatic Melanoma1
2RecruitingTreatmentMelanoma1
2RecruitingTreatmentMelanoma and Brain Metastases1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentProstate Cancers1
2RecruitingTreatmentRecurrent Melanoma / Stage IIIB Melanoma / Stage IIIC Melanoma / Stage IV Melanoma1
2RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2RecruitingTreatmentRecurrent Uveal Melanoma / Stage IV Uveal Melanoma1
2SuspendedTreatmentCervical Cancers1
2SuspendedTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2SuspendedTreatmentPoorly Differentiated Thyroid Gland Carcinoma / Recurrent Thyroid Gland Carcinoma / Stage IVA Thyroid Gland Follicular Carcinoma / Stage IVA Thyroid Gland Papillary Carcinoma / Stage IVB Thyroid Gland Follicular Carcinoma / Stage IVB Thyroid Gland Papillary Carcinoma / Stage IVC Thyroid Gland Follicular Carcinoma / Stage IVC Thyroid Gland Papillary Carcinoma1
2SuspendedTreatmentRecurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2WithdrawnTreatmentCancers / GNA11 Mutation-positive Metastatic Melanoma / GNAQ Mutation-positive Metastatic Melanoma / Metastatic Uveal Melanoma1
2, 3RecruitingTreatmentMicropapillary Serous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
3Active Not RecruitingTreatmentMelanoma4
3Not Yet RecruitingTreatmentMelanoma1
3RecruitingTreatmentMelanoma1
3RecruitingTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
4Not Yet RecruitingTreatmentMelanoma1
Not AvailableRecruitingNot AvailableMalignant Melanoma Stage IIIc / Malignant Melanoma Stage IV1
Not AvailableRecruitingBasic ScienceCancer, Breast1
Not AvailableRecruitingTreatmentNeoplasms / Neoplasms, Advanced Solid / Recurrent Solid Neoplasm1
PharmacodynamicsWhen 1 mg and 2 mg trametinib is given to patients with BRAF V600 mutation-positive melanoma, an inhibition of phosphorylated ERK and Ki67, and an increase in p27 was observed. These changes indicate that trametinib caused a decrease in cell proliferation and an increase in apoptosis, respectively.
Mechanism of actionTrametinib is a reversible, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. Trametinib helps with melanoma with the BRAF V600E or V600K as the mutation results in the constitutive activation of the BRAF pathway which includes MEK1 and MEK2.
TargetKindPharmacological actionActionsOrganismUniProt ID
Dual specificity mitogen-activated protein kinase kinase 1Proteinyes
inhibitor
HumanQ02750 details
Dual specificity mitogen-activated protein kinase kinase 2Proteinyes
inhibitor
HumanP36507 details
Related Articles
AbsorptionTrametinib is rapidly absorbed. When an oral administration of trametinib was given to patients with BRAF V600 mutation-positive melanoma, peak plasma concentration occurred 1.5 hours post-dose (Tmax). A single 2 mg oral dose has a bioavailability of 72%. When a dose of 2mg/day is given, the peak plasma concentration (Cmax) is 22.2 ng/mL.
Volume of distribution

Apparent volume of distribution (Vd/F) = 214 L

Protein binding97.4% bound to human plasma proteins.
Metabolism

Trametinib is metabolized predominantly via deacetylation alone or with mono-oxygenation or in combination with glucuronidation biotransformation pathways in vitro. Deacetylation is likely mediated by hydrolytic enzymes, such as carboxyl-esterases or amidases. The cytochrome P450 enzyme system is not involved with the metabolism of trametinib. The predominant circulating component in the plasma is the parent compound.

Route of elimination80% of the dose is excreted in the feces. <20% of the dose is excreted in the urine with <0.1% of the excreted dose in the form of the parent compound.
Half lifeElimination half-life = 3.9-4.8 days.
Clearance

Apparent clearance = 4.9 L/h.

ToxicityMost common adverse reactions (≥20%) for trametinib include rash, diarrhea, and lymphedema.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Trametinib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Trametinib.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Trametinib.Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Trametinib.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Trametinib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trametinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Trametinib.Approved, Investigational
DabrafenibThe risk or severity of adverse effects can be increased when Trametinib is combined with Dabrafenib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Trametinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Trametinib.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Trametinib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trametinib.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Trametinib.Approved, Illicit
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Trametinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Trametinib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trametinib.Approved, Vet Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Trametinib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Trametinib.Approved, Investigational
Food Interactions
  • When taken with a high-fat, high-calorie meal, AUC and Cmax decreased. Tmax was also prolonged compared to fasted conditions.
References
Synthesis ReferenceNot Available
General References
  1. Salama AK, Kim KB: Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr;14(5):619-27. doi: 10.1517/14656566.2013.770475. Epub 2013 Feb 23. [PubMed:23432625 ]
External Links
ATC CodesL01XE25
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (517 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9733
Blood Brain Barrier+0.8217
Caco-2 permeable-0.5193
P-glycoprotein substrateNon-substrate0.5945
P-glycoprotein inhibitor INon-inhibitor0.6449
P-glycoprotein inhibitor IINon-inhibitor0.8622
Renal organic cation transporterNon-inhibitor0.899
CYP450 2C9 substrateNon-substrate0.7215
CYP450 2D6 substrateNon-substrate0.8232
CYP450 3A4 substrateSubstrate0.5735
CYP450 1A2 substrateNon-inhibitor0.8599
CYP450 2C9 inhibitorNon-inhibitor0.5775
CYP450 2D6 inhibitorNon-inhibitor0.9521
CYP450 2C19 inhibitorNon-inhibitor0.8769
CYP450 3A4 inhibitorNon-inhibitor0.836
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9337
Ames testAMES toxic0.5498
CarcinogenicityNon-carcinogens0.8078
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3412 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9539
hERG inhibition (predictor II)Non-inhibitor0.6602
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral0.5 mg
TabletOral1 mg
TabletOral2 mg
Tablet, film coatedOral.5 mg/1
Tablet, film coatedOral0.5 mg
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral2 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7378423 No2005-09-132025-09-13Us
US8580304 No2012-01-282032-01-28Us
US8703781 No2010-10-152030-10-15Us
US8835443 No2005-09-132025-09-13Us
US9155706 No2012-01-282032-01-28Us
US9271941 No2012-01-282032-01-28Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0307 mg/mLALOGPS
logP3.45ALOGPS
logP3.18ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)12.6ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area102.06 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity156.38 m3·mol-1ChemAxon
Polarizability55.43 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridopyrimidines
Sub ClassNot Available
Direct ParentPyridopyrimidines
Alternative Parents
Substituents
  • Acetanilide
  • Pyridopyrimidine
  • N-acetylarylamine
  • Anilide
  • N-arylamide
  • Aniline or substituted anilines
  • Aminopyridine
  • Fluorobenzene
  • Halobenzene
  • Iodobenzene
  • Pyridinone
  • Pyrimidone
  • Methylpyridine
  • Benzenoid
  • Aryl halide
  • Aryl fluoride
  • Pyrimidine
  • Aryl iodide
  • Monocyclic benzene moiety
  • Pyridine
  • Heteroaromatic compound
  • Acetamide
  • Vinylogous amide
  • Urea
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Amino acid or derivatives
  • Lactam
  • Carboxylic acid derivative
  • Azacycle
  • Secondary amine
  • Organic oxide
  • Organic nitrogen compound
  • Amine
  • Hydrocarbon derivative
  • Carbonyl group
  • Organic oxygen compound
  • Organopnictogen compound
  • Organohalogen compound
  • Organofluoride
  • Organoiodide
  • Organonitrogen compound
  • Organooxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Receptor signaling protein tyrosine phosphatase activity
Specific Function:
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2...
Gene Name:
MAP2K1
Uniprot ID:
Q02750
Molecular Weight:
43438.65 Da
References
  1. Salama AK, Kim KB: Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr;14(5):619-27. doi: 10.1517/14656566.2013.770475. Epub 2013 Feb 23. [PubMed:23432625 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).
Gene Name:
MAP2K2
Uniprot ID:
P36507
Molecular Weight:
44423.735 Da
References
  1. Salama AK, Kim KB: Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother. 2013 Apr;14(5):619-27. doi: 10.1517/14656566.2013.770475. Epub 2013 Feb 23. [PubMed:23432625 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Comments
comments powered by Disqus
Drug created on June 24, 2013 15:36 / Updated on January 20, 2017 03:17